Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-finding study of YMI024 in stable coronary artery disease with elevated hsCRP
jRCT2031260551Phase 2Not yet recruiting
- Sponsor
- Novartis
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of YMI024 in coronary arteriosclerosis (6 arms), sponsored by Novartis. Primary endpoint: Change from baseline in log-transformed IL-6. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
YMI024
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on jRCT2031260551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260551.